Market Closed -
Nasdaq
04:00:00 2024-05-31 pm EDT
|
5-day change
|
1st Jan Change
|
2.86
USD
|
-1.38%
|
|
-7.74%
|
-50.69%
|
Fiscal Period: June |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
178.2
|
437.8
|
320.9
|
80.56
|
43.84
|
19.06
|
-
|
-
|
Enterprise Value (EV)
1 |
178.2
|
425.4
|
320.9
|
80.56
|
43.84
|
19.06
|
19.06
|
19.06
|
P/E ratio
|
-10.4
x
|
-8.1
x
|
-6.33
x
|
-1.38
x
|
-1.38
x
|
0.79
x
|
-0.5
x
|
-0.77
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
36.3
x
|
15.1
x
|
12.6
x
|
1.98
x
|
0.9
x
|
0.29
x
|
3.05
x
|
0.76
x
|
EV / Revenue
|
36.3
x
|
15.1
x
|
12.6
x
|
1.98
x
|
0.9
x
|
0.29
x
|
3.05
x
|
0.76
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-6,013,028
x
|
13,121,162
x
|
-9,821,453
x
|
-1,636,506
x
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
0%
|
-0%
|
-0%
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
7.76
x
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
3,565
|
5,300
|
5,630
|
6,658
|
6,663
|
6,663
|
-
|
-
|
Reference price
2 |
50.00
|
82.60
|
57.00
|
12.10
|
6.580
|
2.860
|
2.860
|
2.860
|
Announcement Date
|
8/28/19
|
9/9/20
|
9/2/21
|
9/8/22
|
9/26/23
|
-
|
-
|
-
|
Fiscal Period: June |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
4.915
|
28.91
|
25.54
|
40.7
|
48.82
|
65.3
|
6.25
|
25
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-46.24
|
-24.54
|
-69.68
|
-75.48
|
-36.76
|
23.16
|
-41.13
|
-29.35
|
Operating Margin
|
-940.9%
|
-84.88%
|
-272.9%
|
-185.48%
|
-75.31%
|
35.48%
|
-658.13%
|
-117.41%
|
Earnings before Tax (EBT)
1 |
-16.82
|
-46.02
|
-50.57
|
-54.45
|
-31.84
|
26.57
|
-39.95
|
-25.87
|
Net income
1 |
-16.82
|
-46.02
|
-50.58
|
-54.45
|
-31.84
|
26.57
|
-39.95
|
-25.87
|
Net margin
|
-342.2%
|
-159.15%
|
-198.06%
|
-133.8%
|
-65.22%
|
40.69%
|
-639.22%
|
-103.49%
|
EPS
2 |
-4.800
|
-10.20
|
-9.000
|
-8.800
|
-4.780
|
3.620
|
-5.690
|
-3.710
|
Free Cash Flow
|
-29.64
|
33.36
|
-32.67
|
-49.22
|
-
|
-
|
-
|
-
|
FCF margin
|
-603.05%
|
115.39%
|
-127.95%
|
-120.95%
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/28/19
|
9/9/20
|
9/2/21
|
9/8/22
|
9/26/23
|
-
|
-
|
-
|
Fiscal Period: June |
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
18.22
|
9.694
|
11.41
|
8.73
|
32.74
|
5.894
|
1.457
|
65.3
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-11.24
|
-21.56
|
-16.2
|
-18.22
|
8.926
|
-16.39
|
-11.08
|
55.28
|
-11.93
|
-9.829
|
-10.87
|
-14.8
|
-18.8
|
Operating Margin
|
-61.66%
|
-222.38%
|
-141.9%
|
-208.69%
|
27.27%
|
-278.1%
|
-760.47%
|
84.66%
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-5.766
|
-8.725
|
-16.06
|
-16.62
|
10.25
|
-15.44
|
-10.03
|
56.37
|
-11.06
|
-9.127
|
-9.966
|
-14.2
|
-18.3
|
Net income
1 |
-5.766
|
-8.725
|
-16.06
|
-16.62
|
10.25
|
-15.44
|
-10.03
|
56.37
|
-11.06
|
-9.127
|
-9.408
|
-11.3
|
-14.6
|
Net margin
|
-31.64%
|
-90%
|
-140.73%
|
-190.42%
|
31.32%
|
-261.93%
|
-688.33%
|
86.33%
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-1.000
|
-1.400
|
-2.400
|
-2.400
|
1.600
|
-2.320
|
-1.507
|
8.460
|
-1.660
|
-1.370
|
-1.407
|
-1.700
|
-2.200
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/10/22
|
5/23/22
|
9/8/22
|
11/14/22
|
2/9/23
|
5/11/23
|
9/26/23
|
11/9/23
|
2/13/24
|
5/9/24
|
-
|
-
|
-
|
Fiscal Period: June |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
12.3
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-29.6
|
33.4
|
-32.7
|
-49.2
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-26.4%
|
-
|
-22.4%
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
191.9
|
-
|
142.2
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
7.350
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-7.880
|
-
|
-
|
-
|
Capex
|
0.22
|
0.89
|
0.71
|
0.48
|
-
|
-
|
-
|
-
|
Capex / Sales
|
4.42%
|
3.09%
|
2.77%
|
1.18%
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/28/19
|
9/9/20
|
9/2/21
|
9/8/22
|
9/26/23
|
-
|
-
|
-
|
Last Close Price
2.86
USD Average target price
22.67
USD Spread / Average Target +692.54% Consensus |
1st Jan change
|
Capi.
|
---|
| -50.69% | 19.06M | | +43.36% | 54.63B | | -5.31% | 39.92B | | +37.52% | 38.82B | | +14.75% | 26.86B | | -12.56% | 26.22B | | -22.45% | 18.78B | | +25.12% | 12.21B | | +0.04% | 12.16B | | +26.04% | 11.94B |
Other Biotechnology & Medical Research
|